Jean-Christophe is a member of the Scientific Board of the International Society of Pharmacovigilance (ISoP), graduated in medicine (MD) and neuropharmacology (PhD) from the universities of Rennes and Paris Sorbonne (France). After his medical residency, he completed a research program in biochemistry and intracellular signaling at the National Institute of Medical Research (Inserm, France).
In 1991, he re-oriented toward global clinical research at Roche (Basel), Rhône-Poulenc (Paris and Tokyo), and Novartis (Basel), where he conducted multinational trials in neurodegenerative diseases and cerebrovascular disorders.
From 2001 until June 2020, he led Bayer’s regional pharmacovigilance teams based in Osaka, Beijing then Singapore. In 2017 he was appointed by Bayer as head of pharmacovigilance policy strategy with a global scope, also taking an active role within the International Pharmacovigilance Group (IPVG) of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
On July 1st 2022, Jean-Christophe Delumeau, was appointed as a board director of the Institute of Pharmacovigilance engaging into the development of innovative systems aimed at facilitating the improvement of the global pharmacovigilance regulatory framework, in collaboration with Public Health stakeholders. Within our Institute, Jean-Christophe is involved in the Global Pharmacovigilance Professional Certification program (GPPC) developed in collaboration with the International Society of Pharmacovigilance (ISoP) that he is serving as a Board and Executive Committee member since 2016. Jean-Christophe is also actively involved in the development of the PVReg platform, an essential component of IPV’s Knowledge Management System. More details on his background on https://www.linkedin.com/in/delumeau/